Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083

Kintara Therapeutics Inc KTRA has announced topline data from Phase 2 study of its lead compound VAL-083, conducted at the MD Anderson Cancer Center.
The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase gene.
Median overall survival (mOS) for the 48 efficacy evaluable patients initially receiving the treatment dose of 30 mg/m2/day is 8.0 months.
While this is not a head-to-head trial, historically, lomustine, the most commonly used chemotherapy for these patients, has demonstrated mOS of 7.2 months.
On the safety front, myelosuppression was the most common adverse event.
In the 30 mg/m2/day starting dose cohort, five patients experienced a serious adverse event possibly related to VAL-083.
For the 83 efficacy evaluable patients who have completed at least one treatment cycle, mOS was 7.5 months.
Price Action: KTRA shares are down 7.93% at $2.09 during the market session on the last check Thursday.